Acadia Pharmaceuticals Announces Executive Leadership Change
September 01 2021 - 4:05PM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
Elena Ridloff, Executive Vice President and Chief Financial Officer
(CFO), will be leaving the company effective September 10, 2021 to
join another biopharmaceutical company. Mark Schneyer, Senior Vice
President, Business Development and Chief Business Officer, will
serve as Acadia’s interim Chief Financial Officer. The company is
conducting a formal search for a new CFO.
“On behalf of all of us at Acadia, I want to thank Elena for her
leadership and contributions which played an important role in
supporting Acadia’s growth and long-term business strategy, and we
wish her well in her future endeavors,” said Steve Davis, Chief
Executive Officer.
“I want to thank my colleagues at Acadia for their partnership
in driving growth of the pimavanserin franchise and advancing
important therapies in our pipeline,” said Ms. Ridloff. “I’m
confident the experienced Acadia team will continue to deliver on
its mission for patients.”
About Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate
life. For more than 25 years we have been working at the forefront
of healthcare to bring vital solutions to people who need them
most. We developed and commercialized the first and only approved
therapy for hallucinations and delusions associated with
Parkinson’s disease psychosis. Our late-stage development efforts
are focused on dementia-related psychosis, negative symptoms of
schizophrenia and Rett syndrome, and in early-stage clinical
research we are exploring novel approaches to pain management, and
cognition and neuropsychiatric symptoms in central nervous system
disorders. For more information, visit us at www.acadia-pharm.com
and follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210901005923/en/
Media Contact: Acadia Pharmaceuticals Inc. Eric Endicott (858)
914-7161 media@acadia-pharm.com Investor Contact: Acadia
Pharmaceuticals Inc. Mark Johnson, CFA (858) 261-2771
ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024